{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By GRETCHEN MORGENSON", "person": [{"rank": 1, "role": "reported", "firstname": "Gretchen", "organization": "", "lastname": "MORGENSON"}]}, "abstract": "Gretchen Morgenson Fair Game column contends beleaguered pharmaceutical firm Valeant is one of growing number of companies that offer two kinds of financial results; holds there are those that comply with accepted accounting principles, and those that help executives spin earnings and lull investors.", "type_of_material": "News", "word_count": "1243", "lead_paragraph": "As the Valeant case shows, the proliferation of results not stated according to generally accepted accounting principles makes it harder for investors to evaluate performance.", "pub_date": "2015-11-01T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant Shows the Perils of Fantasy Numbers", "content_kicker": "Fair Game", "print_headline": "Valeant\u2019s Fantastic(al) Numbers", "kicker": "Fair Game"}, "snippet": "As the Valeant case shows, the proliferation of results not stated according to generally accepted accounting principles makes it harder for investors to evaluate performance.", "multimedia": [{"height": 126, "url": "images/2015/10/30/business/30valeant/30valeant-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/30/business/30valeant/30valeant-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/10/30/business/30valeant/30valeant-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/10/30/business/30valeant/30valeant-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/10/30/business/30valeant/30valeant-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/10/30/business/30valeant/30valeant-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/11/01/business/valeant-shows-the-perils-of-fantasy-numbers.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Accounting and Accountants", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Regulation and Deregulation of Industry", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Company Reports", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Securities and Exchange Commission", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}], "blog": [], "_id": "56339f5538f0d85e68a21d0b", "source": "The New York Times"}